154 related articles for article (PubMed ID: 29956798)
1. Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer.
Gou HF; Zhou L; Huang J; Chen XC
Mol Med Rep; 2018 Aug; 18(2):2335-2341. PubMed ID: 29956798
[TBL] [Abstract][Full Text] [Related]
2. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model.
Adah D; Yang Y; Liu Q; Gadidasu K; Tao Z; Yu S; Dai L; Li X; Zhao S; Qin L; Qin L; Chen X
Cell Commun Signal; 2019 Apr; 17(1):32. PubMed ID: 30979375
[TBL] [Abstract][Full Text] [Related]
5. Hypothermic microenvironment plays a key role in tumor immune subversion.
Du G; Liu Y; Li J; Liu W; Wang Y; Li H
Int Immunopharmacol; 2013 Oct; 17(2):245-53. PubMed ID: 23831011
[TBL] [Abstract][Full Text] [Related]
6. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic chemotherapy in two mouse colon cancer models.
Taniura T; Iida Y; Kotani H; Ishitobi K; Tajima Y; Harada M
Cancer Sci; 2020 Oct; 111(10):3527-3539. PubMed ID: 32816355
[TBL] [Abstract][Full Text] [Related]
8. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment.
Gangaplara A; Martens C; Dahlstrom E; Metidji A; Gokhale AS; Glass DD; Lopez-Ocasio M; Baur R; Kanakabandi K; Porcella SF; Shevach EM
PLoS Pathog; 2018 Apr; 14(4):e1006985. PubMed ID: 29672594
[TBL] [Abstract][Full Text] [Related]
9. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression.
Nakamura S; Yaguchi T; Kawamura N; Kobayashi A; Sakurai T; Higuchi H; Takaishi H; Hibi T; Kawakami Y
J Immunother; 2014; 37(2):63-72. PubMed ID: 24509168
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous inoculation position affects the immune environment in CT26 carcinomas.
Fu X; Yang Y; Xie J; Pan X; Yang X; Du Z; Hao E
Biochem Biophys Res Commun; 2019 Apr; 512(2):244-249. PubMed ID: 30879760
[TBL] [Abstract][Full Text] [Related]
11. A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity.
Tao H; Cheng L; Liu L; Wang H; Jiang Z; Qiang X; Xing L; Xu Y; Cai X; Yao J; Wang M; Qiu Z
Cancer Lett; 2020 Nov; 493():91-101. PubMed ID: 32805322
[TBL] [Abstract][Full Text] [Related]
12. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
[TBL] [Abstract][Full Text] [Related]
13. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
Filatenkov A; Baker J; Mueller AM; Kenkel J; Ahn GO; Dutt S; Zhang N; Kohrt H; Jensen K; Dejbakhsh-Jones S; Shizuru JA; Negrin RN; Engleman EG; Strober S
Clin Cancer Res; 2015 Aug; 21(16):3727-39. PubMed ID: 25869387
[TBL] [Abstract][Full Text] [Related]
14. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Chuang HY; Chang YF; Liu RS; Hwang JJ
PLoS One; 2014; 9(10):e109992. PubMed ID: 25333973
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number.
Rossowska J; Pajtasz-Piasecka E; Anger N; Wojas-Turek J; Kicielińska J; Piasecki E; Duś D
J Immunother; 2014; 37(9):427-39. PubMed ID: 25304726
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
18. Generation of cancer-specific CD8(+) CD69(+) cells inhibits colon cancer growth.
Lan B; Zhang J; Lu D; Li W
Immunobiology; 2016 Jan; 221(1):1-5. PubMed ID: 26314763
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
